(VIANEWS) – Zynex (ZYXI), Eli Lilly and Company (LLY), FMC Technologies (FTI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Zynex (ZYXI)
18.2% sales growth and 17.3% return on equity
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Earnings Per Share
As for profitability, Zynex has a trailing twelve months EPS of $0.27.
PE Ratio
Zynex has a trailing twelve months price to earnings ratio of 42.15. Meaning, the purchaser of the share is investing $42.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.3%.
Moving Average
Zynex’s worth is below its 50-day moving average of $12.54 and way higher than its 200-day moving average of $9.92.
Volume
Today’s last reported volume for Zynex is 181319 which is 16.38% below its average volume of 216842.
Revenue Growth
Year-on-year quarterly revenue growth declined by 3.1%, now sitting on 184.32M for the twelve trailing months.
2. Eli Lilly and Company (LLY)
17.6% sales growth and 50.75% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.77.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 130.27. Meaning, the purchaser of the share is investing $130.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 50.75%.
Moving Average
Eli Lilly and Company’s worth is under its 50-day moving average of $761.53 and way higher than its 200-day moving average of $628.95.
Volume
Today’s last reported volume for Eli Lilly and Company is 1949700 which is 36.73% below its average volume of 3081640.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 30.8% and 3630%, respectively.
3. FMC Technologies (FTI)
17.1% sales growth and 5.46% return on equity
TechnipFMC plc engages in the energy projects, technologies, and systems and services businesses in Europe, Central Asia, North America, Latin America, the Asia Pacific, Africa, the Middle East, and internationally. It operates through two segments: Subsea and Surface Technologies. The Subsea segment engages in the design, engineering, procurement, manufacturing, fabrication, installation, and life of field services for subsea systems, subsea field infrastructure, and subsea pipe systems used in oil and gas production and transportation. It provides subsea production and processing system; flexible pipe; subsea umbilicals, risers, and flowlines; vessels; robotics; well and asset services; and Subsea Studio for optimizing the development, execution, and operation of current and future subsea fields. The Surface Technologies segment designs, manufactures, and services products and systems used in land and shallow water exploration and production of crude oil and natural gas. This segment offers drilling; surface wellheads and production trees systems; iComplete, a pressure control system; fracturing tree and manifold systems; flexible pipes; safety and integrity systems, multiphase meter modules, in-line separation and processing systems, and standard pumps; well control and integrity systems; separation and processing systems; skid systems; and flow measurement and automation solutions. It also offers planning, testing and installation, commissioning, operations, replacement and upgrade, maintenance, storage, preservation, intervention, integrity, decommissioning, and abandonment; and supplies flowline products and services. TechnipFMC plc was founded in 1884 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, FMC Technologies has a trailing twelve months EPS of $0.12.
PE Ratio
FMC Technologies has a trailing twelve months price to earnings ratio of 215.58. Meaning, the purchaser of the share is investing $215.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.46%.
Moving Average
FMC Technologies’s value is higher than its 50-day moving average of $24.58 and way above its 200-day moving average of $20.99.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.9%, now sitting on 8.15B for the twelve trailing months.
4. Agree Realty Corporation (ADC)
14.5% sales growth and 3.47% return on equity
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of June 30, 2020, the Company owned and operated a portfolio of 936 properties, located in 46 states and containing approximately 18.4 million square feet of gross leasable area. The common stock of Agree Realty Corporation is listed on the New York Stock Exchange under the symbol "ADC".
Earnings Per Share
As for profitability, Agree Realty Corporation has a trailing twelve months EPS of $1.7.
PE Ratio
Agree Realty Corporation has a trailing twelve months price to earnings ratio of 33.27. Meaning, the purchaser of the share is investing $33.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.47%.
Volume
Today’s last reported volume for Agree Realty Corporation is 1111350 which is 3.86% above its average volume of 1069950.
5. Erie Indemnity Company (ERIE)
11.9% sales growth and 30.15% return on equity
Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. The company provides sales, underwriting, policy issuance, and renewal services for the policyholders on behalf of the Erie Insurance Exchange. It also offers sales related services, including agent compensation, and sales and advertising support services; and underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. Erie Indemnity Company was incorporated in 1925 and is based in Erie, Pennsylvania.
Earnings Per Share
As for profitability, Erie Indemnity Company has a trailing twelve months EPS of $9.28.
PE Ratio
Erie Indemnity Company has a trailing twelve months price to earnings ratio of 41.14. Meaning, the purchaser of the share is investing $41.14 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 30.15%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Apr 8, 2024, the estimated forward annual dividend rate is 5.1 and the estimated forward annual dividend yield is 1.34%.
Volume
Today’s last reported volume for Erie Indemnity Company is 56525 which is 48.36% below its average volume of 109461.
6. ExlService Holdings (EXLS)
8.8% sales growth and 22.4% return on equity
ExlService Holdings, Inc. operates as a data analytics, and digital operations and solutions company in the United States and internationally. It operates through Insurance, Healthcare, Analytics, and Emerging Business segments. The company provides digital operations and solutions and analytics-driven services across the insurance industry in areas, such as claims processing, premium and benefit administration, agency management, account reconciliation, policy research, underwriting support, new business acquisition, policy servicing, premium audit, surveys, billing and collection, commercial and residential survey, and customer service using digital technology, artificial intelligence, machine learning, and advanced automation; digital customer acquisition services using a software-as-a-service delivery model through LifePRO and LISS platforms; subrogation services; and Subrosource software platform, an end-to-end subrogation platform. It also offers CareRadius, an integrated care management offering; and health care services related to care management, utilization management, disease management, payment integrity, revenue optimization and customer engagement to healthcare payers, providers, pharmacy benefit managers, and life sciences organizations. Further, it offers predictive and prescriptive analytics in the areas of customer acquisition and lifecycle management, risk underwriting and pricing, operational effectiveness, credit and operational risk monitoring and governance, payment integrity and care management, and data management. The company was founded in 1999 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, ExlService Holdings has a trailing twelve months EPS of $1.1.
PE Ratio
ExlService Holdings has a trailing twelve months price to earnings ratio of 26.69. Meaning, the purchaser of the share is investing $26.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.4%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.5%, now sitting on 1.63B for the twelve trailing months.
